These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 27028734)

  • 21. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.
    Mills JR; Kohlhagen MC; Willrich MAV; Kourelis T; Dispenzieri A; Murray DL
    Blood; 2018 Aug; 132(6):670-672. PubMed ID: 29891533
    [No Abstract]   [Full Text] [Related]  

  • 22. Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab.
    Thirkettle S; Russell J; Wilson S; Ganijee T; Kulkarni S; Cavet J; Monaghan PJ
    Ann Clin Biochem; 2020 Mar; 57(2):178-181. PubMed ID: 31791138
    [No Abstract]   [Full Text] [Related]  

  • 23. Analytical sensitivity and diagnostic performance of serum protein electrophoresis on the HYDRAGEL 30 PROTEIN(E) β1-β2 Sebia Hydrasys system.
    Tsui AKY; Thomas D; Hunt A; Estey M; Christensen CL; Higgins T; Sandhu I; Rodriguez-Capote K
    Clin Biochem; 2018 Jan; 51():80-84. PubMed ID: 28916438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
    Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
    Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification.
    Zajec M; Jacobs JFM; de Kat Angelino CM; Dekker LJM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
    J Proteome Res; 2020 Jul; 19(7):2845-2853. PubMed ID: 31895568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.
    Turner KA; Frinack JL; Ettore MW; Tate JR; Graziani MS; Jacobs JFM; Booth RA; McCudden CR; Keren DF; Delgado JC; Zemtsovskaja G; Fullinfaw RO; Caldini A; de Malmanche T; Katakouzinos K; Burke M; Palladini G; Altinier S; Zaninotto M; Righetti G; Melki MT; Bell S; Willrich MAV
    Clin Chem Lab Med; 2020 Mar; 58(4):533-546. PubMed ID: 31940284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
    Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
    Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Oct; 62(11):2223-2232. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
    Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
    J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new approach for rapid detection and typing of serum monoclonal components.
    Cacoub P; Camproux AC; Thiolières JM; Assogba U; Hausfater P; Mallet A; Foglietti MJ; Piette JC; Bernard M
    Clin Chim Acta; 2000 Dec; 302(1-2):105-24. PubMed ID: 11074068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.
    Vakili H; Koorse Germans S; Dong X; Kansagra A; Patel H; Muthukumar A; Hashim IA
    Diagnostics (Basel); 2020 Apr; 10(4):. PubMed ID: 32295157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
    Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
    Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
    Liang S; Feng W; Ma H; Zhang L; Jia C
    Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.
    Liu L; Shurin MR; Wheeler SE
    Clin Biochem; 2020 Jan; 75():40-47. PubMed ID: 31669513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.
    Chen S; Kiguchi T; Nagata Y; Tamai Y; Ikeda T; Kajiya R; Ono T; Sugiyama D; Nishikawa H; Akatsuka Y
    Int J Hematol; 2021 Apr; 113(4):473-479. PubMed ID: 33507526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
    Caldini A; Nozzoli C; Terreni A; Staderini M; Berardi M; Biagioli T; Brogi M; Bosi A
    Clin Chem Lab Med; 2016 Jun; 54(6):991-5. PubMed ID: 26581069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.